Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Asset Writedowns and Impairment (2024 - 2025)

Historic Asset Writedowns and Impairment for Ptc Therapeutics (PTCT) over the last 3 years, with Q3 2025 value amounting to $400000.0.

  • Ptc Therapeutics' Asset Writedowns and Impairment fell 6965.1% to $400000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $161.3 million, marking a year-over-year increase of 1052700.92%. This contributed to the annual value of $159.5 million for FY2024, which is 2674.56% down from last year.
  • Latest data reveals that Ptc Therapeutics reported Asset Writedowns and Impairment of $400000.0 as of Q3 2025, which was down 6965.1% from $100000.0 recorded in Q2 2025.
  • Ptc Therapeutics' Asset Writedowns and Impairment's 5-year high stood at $217.8 million during Q2 2023, with a 5-year trough of $100000.0 in Q2 2025.
  • Over the past 3 years, Ptc Therapeutics' median Asset Writedowns and Impairment value was $859000.0 (recorded in 2024), while the average stood at $63.2 million.
  • In the last 5 years, Ptc Therapeutics' Asset Writedowns and Impairment crashed by 9990.82% in 2024 and then plummeted by 5000.0% in 2025.
  • Ptc Therapeutics' Asset Writedowns and Impairment (Quarter) stood at $217.8 million in 2023, then fell by 26.77% to $159.5 million in 2024, then tumbled by 99.75% to $400000.0 in 2025.
  • Its last three reported values are $400000.0 in Q3 2025, $100000.0 for Q2 2025, and $159.5 million during Q4 2024.